



Tetraphase Pharmaceuticals  
Investor Relations Department  
480 Arsenal Street, Suite 110  
Watertown, MA 02472  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: TTPH

Last Trade:	6.47
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	0.07 <span style="color: green;">▲</span> (+1.094%)
Day Range	6.33 - 6.55
52-Week Range	3.11 - 9.93
Volume	272,911


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Since the company's inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- Oct 16, 2017*  
[Tetraphase Pharmaceuticals Appoints Kam Unninarav as Chief Financial Officer](#)
- Oct 4, 2017*  
[Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017](#)
- Sep 25, 2017*  
[Tetraphase Pharmaceuticals to Present Data at IDWeek 2017](#)
- Sep 11, 2017*  
[Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections](#)
- Sep 5, 2017*  
[Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences](#)

## Financials & Filings [\[ View all \]](#)

- Mar 13, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)